Zoetis Inc. (NYSE:ZTS) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Consensus "Hold": Fifteen analysts cover Zoetis with a consensus recommendation of Hold (1 sell, 7 hold, 7 buy) and an average 12‑month price target of $151.75.
• Earnings and guidance: Zoetis beat Q results (EPS $1.48 vs. $1.40; revenue $2.39B vs. $2.36B) and set FY2026 guidance of 7.00–7.10 EPS, roughly in line with the street average of 7.01.
• Valuation and shareholder metrics: Shares opened around $114.22 (52‑week range $112.97–$172.23) with a market cap of ~$48B, P/E ≈ 19 and a quarterly dividend of $0.53 (annualized yield ~1.9%); institutional investors own about 92.8% of the stock.

Shares of Zoetis Inc. (NYSE:ZTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the fifteen ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $151.75.

ZTS has been the subject of several recent research reports. BTIG Research reissued a "buy" rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Citigroup initiated coverage on Zoetis in a research note on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price target for the company. UBS Group lowered their price target on Zoetis from $136.00 to $130.00 and set a "neutral" rating for the company in a research note on Tuesday, April 28th. Piper Sandler reissued a "neutral" rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, Leerink Partners reissued a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th.

Institutional Investors Weigh In On Zoetis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LGT Fund Management Co Ltd. lifted its holdings in Zoetis by 1,273.6% in the 1st quarter. LGT Fund Management Co Ltd. now owns 33,434 shares of the company's stock worth $3,952,000 after purchasing an additional 31,000 shares during the last quarter. Global Assets Advisory LLC acquired a new stake in Zoetis in the 1st quarter worth approximately $38,000. International Assets Investment Management LLC lifted its holdings in Zoetis by 24.9% in the 1st quarter. International Assets Investment Management LLC now owns 4,885 shares of the company's stock worth $573,000 after purchasing an additional 973 shares during the last quarter. Associated Banc Corp lifted its holdings in Zoetis by 9.9% in the 1st quarter. Associated Banc Corp now owns 75,959 shares of the company's stock worth $8,979,000 after purchasing an additional 6,842 shares during the last quarter. Finally, Valmark Advisers Inc. lifted its holdings in Zoetis by 7.7% in the 1st quarter. Valmark Advisers Inc. now owns 1,747 shares of the company's stock worth $207,000 after purchasing an additional 125 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 0.1%

Shares of NYSE ZTS opened at $114.22 on Monday. The stock has a market cap of $48.05 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.76 and a beta of 0.87. The business has a 50 day simple moving average of $119.93 and a 200 day simple moving average of $124.53. Zoetis has a 52 week low of $112.97 and a 52 week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts predict that Zoetis will post 7.01 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis's payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.